Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1977-4-15
|
| pubmed:abstractText |
A patient with thioridazine-hydrochloride-associated agranulocytosis is described and eight previously reported cases are reviewed. This complication is most likely due to a direct toxic effect on the bone marrow. As in our case, markers for an immunologically mediated mechanism have not been found. Thioridazine-hydrochloride-associated agranulocytosis usually occurs between the fifth and 11th week of therapy and is not related to the total dose of drug received. Three of the nine patients with thioridazine-hydrochloride-associated agranulocytosis have died from infectious complications. Thus, careful monitoring for infection and prompt therapy are indicated.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0038-4348
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
70
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
110-1
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1977
|
| pubmed:articleTitle |
Thioridazine-hydrochloride-associated agranulocytosis.
|
| pubmed:publicationType |
Journal Article,
Case Reports
|